Pipeline
Aldeyra Is a Well-Capitalized Biotechonology Company with a Broad Immunology Pipeline
Product Candidates | Disease Targets | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
---|---|---|---|---|---|---|
ReproxalapDisease Targets: Dry Eye Disease Type (ophthalmic solution) Option agreement w/AbbVie | Dry Eye Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ReproxalapDisease Targets: Allergic Conjunctivitis Type (ophthalmic solution) Option agreement w/AbbVie | Allergic Conjunctivitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Moderate Alcoholic Hepatitis Type (oral administration) | Moderate Alcoholic Hepatitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Sjögren-Larsson Syndrome Type (oral administration) | Sjögren-Larsson Syndrome | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-246Disease Targets: Atopic Dermatitis Type (oral administration) | Atopic Dermatitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-246Disease Targets: Metabolic Disease Type (oral administration) | Metabolic Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-248Disease Targets: Dry Age-Related Macular Degeneration / Geographical Atrophy Type (intravitreal injection) | Dry Age-Related Macular Degeneration / Geographical Atrophy | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-2191*Disease Targets: Retinitis Pigmentosa Type (intravitreal injection) | Retinitis Pigmentosa | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
*U.S. FDA Orphan-Drug Designated